---
title: "Tonix Pharmaceuticals posts investor deck spotlighting TONMYA fibromyalgia launch strategy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291977847.md"
description: "Tonix Pharmaceuticals highlighted early commercial traction for TONMYA, launched Nov. 17, 2025, reporting USD 3.7 million in Q1'26 net sales and USD 5.1 million cumulatively by Mar. 31, 2026, with over 2,600 prescribers. The company holds USD 185.5 million in cash with no debt, projecting a runway into early Q2'27. Pipeline updates include TNX-4800 Lyme disease studies planned for 1H'27, while TNX-1500 and TNX-2900 Phase 2 trials are scheduled for late 2026 and early 2027 respectively."
datetime: "2026-07-07T21:02:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291977847.md)
  - [en](https://longbridge.com/en/news/291977847.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291977847.md)
generator: "portal-rs"
---

# Tonix Pharmaceuticals posts investor deck spotlighting TONMYA fibromyalgia launch strategy

-   Tonix highlighted early commercial traction for TONMYA, launched Nov. 17, 2025, with 1Q’26 net sales of USD 3.7 million. \* Net sales reached USD 5.1 million from Nov. 17, 2025 to Mar. 31, 2026; more than 2,600 prescribers wrote TONMYA prescriptions. \* Cash and cash equivalents totaled about USD 185.5 million as of Mar. 31, 2026; no debt; cash runway expected into early Q2’27. \* Pipeline focus includes TNX-4800 Lyme disease prevention study planned for 1H’27; TNX-1500 Phase 2 planned 2H’26; TNX-2900 Phase 2 planned 1Q’27. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [TNXP.US](https://longbridge.com/en/quote/TNXP.US.md)

## Related News & Research

- [Tonix CEO Seth Lederman acquires 2,000 common shares for $27,580](https://longbridge.com/en/news/297513102.md)
- [Tonix Pharma director Richard H. Bagger acquires common shares worth $12,600](https://longbridge.com/en/news/296784374.md)
- [Avient’s Dyneema to debut SK80 mooring fiber at SMM trade fair](https://longbridge.com/en/news/297191045.md)
- [AgroGalaxy delays 2025 results release to Nov. 30, 2026](https://longbridge.com/en/news/297440664.md)
- [Exmar announces availability of 2026 half-year results release](https://longbridge.com/en/news/296992548.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**